Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double Dose Furmonertinib with Intrathecal Chemotherapy for EGFR-mutant NSCLC with Leptomeningeal Metastasis
NCT06339242Phase 2Recruiting
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Brain Hospital of Nanjing Medical University. Started Jan 2024; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06339242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06339242.